常山药业(300255) - 2024 Q3 - 季度财报

Revenue and Profitability - Revenue for Q3 2024 was CNY 216,245,003.62, a decrease of 32.26% compared to the same period last year[2] - Net profit attributable to shareholders was CNY 54,192,753.72, an increase of 123.31% year-on-year[2] - Net profit excluding non-recurring items was CNY 25,517,268.01, up 110.92% compared to the previous year[2] - Basic earnings per share rose to CNY 0.06, a 124.00% increase from the same period last year[2] - The company reported a net loss for the quarter, with total costs exceeding revenues, highlighting the need for strategic adjustments moving forward[14] - The net profit for the third quarter of 2024 was -27,806,023.52 CNY, compared to -394,940,113.26 CNY in the same period last year, showing an improvement[15] - The total comprehensive income for the period was -27,804,018.75 CNY, compared to -395,868,638.95 CNY in the previous year, showing a notable improvement[16] Cash Flow and Liquidity - Operating cash flow net amount increased by 221.88% year-to-date, totaling CNY 150,346,631.17[2] - Cash and cash equivalents increased by 118.55% year-on-year, driven by improved operating cash flow[8] - The net cash flow from operating activities for Q3 2024 was ¥150,346,631.17, a significant improvement compared to the net cash outflow of ¥123,360,486.25 in Q3 2023[18] - Total cash inflow from operating activities was ¥862,960,667.08, while cash outflow was ¥712,614,035.91, resulting in a net cash inflow[18] - The company reported a total cash and cash equivalents balance of ¥314,190,232.52 at the end of Q3 2024, up from ¥278,708,793.73 at the end of Q3 2023[18] - The company received cash related to operating activities amounting to ¥42,433,202.33, down from ¥74,740,361.76 in the previous year[18] - Total cash outflow for operating activities was ¥712,614,035.91, a decrease from ¥1,517,341,555.87 in Q3 2023[18] Assets and Liabilities - Total assets at the end of the period were CNY 4,686,231,930.31, reflecting a 1.95% increase from the end of the previous year[2] - Current liabilities totaled CNY 1,974,421,339.95, an increase from CNY 1,920,921,469.78, marking a rise of approximately 2.8%[14] - The total liabilities amounted to CNY 2,914,343,874.21, up from CNY 2,796,761,912.30, reflecting an increase of approximately 4.2%[14] - The company's equity attributable to shareholders reached CNY 1,818,949,472.07, slightly up from CNY 1,811,657,375.57, indicating a growth of about 0.4%[14] - Non-current assets increased to CNY 2,445,755,711.69 from CNY 2,320,594,888.49, showing a growth of about 5.4%[13] Shareholder Information - The total number of common shareholders at the end of the reporting period is 40,810[9] - The largest shareholder, Gao Shuhua, holds 30.54% of the shares, totaling 280,644,728 shares, with 180,920,000 shares pledged[9] - The total number of restricted shares at the beginning of the period was 3,216,020, with 232,826 shares released during the period[11] - The company has a total of 1,147,500 restricted shares held by senior executives, which will be unlocked at a rate of 25% annually during their tenure[11] - The total number of shares held by the top ten shareholders includes significant pledges, indicating potential financial leverage[9] Operational Performance - The company experienced a 31.20% decrease in revenue year-on-year, primarily due to price reductions from centralized procurement[6] - The total operating revenue for the third quarter of 2024 was CNY 784,021,902.08, a decrease of approximately 31.3% compared to CNY 1,139,615,425.99 in the same period last year[14] - The total operating costs for the third quarter of 2024 were CNY 874,012,625.11, down from CNY 1,439,650,840.38, reflecting a reduction of about 39.4%[14] - Accounts receivable increased to CNY 266,126,748.26 from CNY 206,134,679.26, representing a growth of approximately 29.1%[13] - Inventory decreased to CNY 1,448,016,763.76 from CNY 1,644,283,353.62, indicating a decline of about 11.9%[13] Research and Development - Research and development expenses decreased by 76.69% year-on-year, attributed to reduced direct investment in R&D projects[7] - Research and development expenses amounted to 23,438,244.55 CNY, compared to 100,561,746.37 CNY in the previous year, reflecting a significant reduction[15] Other Income and Expenses - The company reported a significant increase in other income by 108.24% year-on-year, mainly due to project completion and subsidy funds being recognized as other income[7] - The company recorded other income of 30,589,042.11 CNY, which is an increase from 14,689,581.79 CNY year-on-year[15] - The company reported a financial expense of 67,213,216.37 CNY, down from 76,239,903.86 CNY, indicating a decrease of about 12.6%[15] - The sales expenses for the quarter were 42,991,269.39 CNY, down from 348,418,548.74 CNY, indicating a significant reduction in costs[15] - The company reported a tax expense of 2,301,122.67 CNY, compared to -11,988,189.41 CNY in the previous year, reflecting a change in tax liabilities[15] Future Outlook - The company has not disclosed any new product developments or market expansion strategies in this report[9] - There are no indications of mergers or acquisitions mentioned in the current financial report[9] - The company has not provided specific future guidance or performance outlook in this report[9] Audit Status - The report for Q3 2024 was not audited, as indicated by the company[19]